Protara Therapeutics, Inc. (TARA) Company Annual Revenue

Protara Therapeutics (TARA) faces risks related to dependence on external investment and a narrow patient segment. The GURU.Markets interface displays the company's current performance metrics, where the latest value is recorded as 0.00. Stability is provided by US laboratories specializing in the treatment of rare tumors. The retention of qualified R&D specialists is guaranteed through stock options, protecting the business's scientific potential from competition.

Protara Therapeutics, Inc. (TARA) - Company Revenue from 07/04/2022 to 11/15/2026

Comprehensive metric breakdowns and analytics for Protara Therapeutics Inc (TARA)

- market price and analyst price targets:

Market Price protaratx.com|TARA - Price Target Chart

- market capitalization details:

Market Valuation Protara|TARA - Total Company Value

- business book valuation details:

Accounting Value of a Share Protara Therapeutics|TARA - Company Book Value|Market-to-Book Ratio protaratx.com|TARA - Cumulative Company Assets

- company liabilities and liquidity data:

- earnings and valuation multiples indicators:

TARA - Net Income|Future Net Profit Protara Therapeutics|TARA - P/E Multiple|Future Price to Earnings Multiple Protara Therapeutics, Inc.|TARA - PEG Multiple|Company Value to EBITDA Protara|TARA - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Protara Therapeutics|TARA - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth protaratx.com|TARA - Earnings per share growth in current year|Net earnings per share change forecast for next year Protara Therapeutics

- sales volume and revenue indicators:

TARA - Revenue and Sales Volume|Company Expected Sales Volume Protara Therapeutics, Inc.|TARA - Market Cap to Revenue|Forward P/S Multiple Protara Tx

Comprehensive company analysis:Protara Therapeutics - TARA

Finished products of Protara Therapeutics, Inc.

This indicator tracks the daily inflow of commercial funds, allowing for a real-time assessment of demand stability. Investors diagnose the fundamental reliability of an asset by monitoring deviations of current inflows from the norm. Analyzing the company's sales revenue can reveal signs of local price overheating. For Protara Therapeutics (TARA), this price action reflects the effectiveness of monetizing its developments. The company is currently implementing robotic automation for molecule screening to accelerate the creation of oncology drugs.

Key competitors